Teva announces positive results from a study assessing a new formulation of Copaxone.
<shortened url>
This Is MS Multiple Sclerosis Community: Knowledge & Support
Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
new formula
2 posts
• Page 1 of 1
new formula
by scorpion » Sat Jun 05, 2010 5:23 pm
-
scorpion - Family Elder
- Posts: 1323
- Joined: Wed Nov 05, 2008 3:00 pm
Advertisement
by DizzyDean » Fri Jun 18, 2010 3:34 pm
The text seems to contradict the conclusion of the study - 12.5% vs 18.1% for those with the new formulation suggests a relative risk INCREASE of nearly 50% for tolerability problems with the new formulation.
A typo? Anybody have a link to the original paper?
A typo? Anybody have a link to the original paper?
Adverse events were reported by 12.5 percent of patients when injecting 20mg/1.0mL and by 18.1 percent of patients when injecting 20mg/0.5mL.
-
DizzyDean - Family Member
- Posts: 45
- Joined: Fri Jun 01, 2007 2:00 pm
2 posts
• Page 1 of 1
Who is online
Users browsing this forum: No registered users
News
Site map
SitemapIndex
RSS Feed
This site does not offer, or claim to offer, medical, legal, or professional advice.
All treatment decisions should always be made with the full knowledge of your physicians.
This is MS does not create, endorse, or republish any content. All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.
This is MS does not create, endorse, or republish any content. All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.
